1. Home
  2. RGA vs UTHR Comparison

RGA vs UTHR Comparison

Compare RGA & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reinsurance Group of America Incorporated

RGA

Reinsurance Group of America Incorporated

HOLD

Current Price

$193.07

Market Cap

12.3B

Sector

Finance

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$489.62

Market Cap

20.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGA
UTHR
Founded
1973
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Life Insurance
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.3B
20.3B
IPO Year
1993
1999

Fundamental Metrics

Financial Performance
Metric
RGA
UTHR
Price
$193.07
$489.62
Analyst Decision
Buy
Buy
Analyst Count
10
12
Target Price
$239.89
$495.08
AVG Volume (30 Days)
361.6K
424.3K
Earning Date
10-30-2025
10-29-2025
Dividend Yield
1.93%
N/A
EPS Growth
18.96
16.08
EPS
12.98
26.38
Revenue
$22,304,000,000.00
$3,128,400,000.00
Revenue This Year
$7.97
$13.64
Revenue Next Year
$10.36
$5.78
P/E Ratio
$14.85
$18.55
Revenue Growth
1.97
13.50
52 Week Low
$159.25
$266.98
52 Week High
$232.97
$492.62

Technical Indicators

Market Signals
Indicator
RGA
UTHR
Relative Strength Index (RSI) 56.87 68.10
Support Level $188.29 $470.13
Resistance Level $194.50 $492.62
Average True Range (ATR) 4.17 10.72
MACD 0.63 -0.53
Stochastic Oscillator 87.85 89.55

Price Performance

Historical Comparison
RGA
UTHR

About RGA Reinsurance Group of America Incorporated

Reinsurance Group of America Inc is an insurance holding company with operations in the United States, Latin America, Canada, Europe, Africa, Asia, and Australia. The core products and services include life reinsurance, living benefits reinsurance, group reinsurance, health reinsurance, financial solutions, facultative underwriting, and product development. The company's operations are divided into traditional and financial solution businesses.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: